Cocrystal Pharma EV/EBIT COCP

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 1.7×; Mar 2021
10-year median: 0.6×
10-year range: 0.0× to 2.5×
Peer median: 2.1×

Cocrystal Pharma has no meaningful EV/EBIT today: it made an operating loss of $10.1M over the last twelve months.

It was last meaningful in Mar 2021, at 1.7×.

On the days it had one over the last ten years, its median was 0.6×, from 0.0× in Mar 2017 to 2.5× in Jan 2021.

EV/EBIT over time

median 0.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	1.7×	1.4×	2.5×
2020	1.4×	0.3×	2.2×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	0.0×	0.0×	0.0×
2016	0.0×	0.0×	2.5×
2015	3.5×	0.4×	3.5×

Against its peers

Companies in Drug Manufacturers - General nearest Cocrystal Pharma's size, closest first, today.

Company	EV/EBIT
COCPCocrystal Pharma	n/m
ATNMActinium Pharmaceuticals	1.2×
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
Peer median	2.1×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Cocrystal Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.